Understanding heart failure in patients with hypertrophic cardiomyopathy through advanced imaging techniques.
Official title: Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMR
Funded at Beth Israel Deaconess Medical Center · NIH-11029028 · Data updated 2026-11-12
This study is looking at how heart failure happens in people with hypertrophic cardiomyopathy (HCM) and how a new medication called mavacamten might help, using special heart scans to understand their condition better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 25, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $777,258 |
| NIH project number | 1R01HL177076-01 |
| Project ID | NIH-11029028 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with hypertrophic cardiomyopathy, particularly those experiencing heart failure symptoms.
✕Less likely to help
Patients with hypertrophic cardiomyopathy who do not exhibit heart failure symptoms may not receive direct benefits from this research.
What this research studies
This research investigates the mechanisms of heart failure in patients with hypertrophic cardiomyopathy (HCM) using cardiac magnetic resonance imaging (CMR). By employing advanced imaging techniques, the study aims to better characterize the different phenotypes of HCM and their response to treatment with a newly approved medication, mavacamten. The research will focus on evaluating heart function, fibrosis, and other critical factors that contribute to heart failure symptoms. Patients may undergo CMR scans to gather detailed information about their heart condition and how it may improve with treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with hypertrophic cardiomyopathy, potentially enhancing their quality of life and reducing heart failure complications.
How similar studies have gone: Previous research has shown promising results using cardiac magnetic resonance imaging to assess heart conditions, indicating that this approach may yield valuable insights into hypertrophic cardiomyopathy.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Nezafat, Reza — Beth Israel Deaconess Medical Center
- Study coordinator: Nezafat, Reza
Related research
Other NIH-funded projects on the same topics.
-
How exercise heart MRI could explain heart failure in hypertrophic cardiomyopathy
Using exercise cardiac MRI, researchers will look at why people with hypertrophic cardiomyopathy develop heart failure and how treatments like the drug mavacamten compare with surgery.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.